Anuh Pharma Limited share price
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The company also develops products, such as anticoagulant, antagonist, anti convulsants, anty-ulcerative, anty-ulcerative, anticholinergics, anti-anemic, antidepressant, and mucolytic agents. It also exports its products. Anuh Pharma Limited wa…Read more
- Market Cap₹ 828 Cr.
- Current Price₹ 82.57
- High / Low₹ 100 / 67
- Stock P/E18.7
- Book Value₹ 35
- Dividend Yield1.79 %
- ROCE15.4 %
- ROE12.10 %
- Face Value₹ 5.0
More figures (10)
- EPS (TTM)₹ 4.41
- Price / Book2.35
- OPM7.4 %
- Debt / Equity0.00
- Sales growth (4Y)13.5 %
- Profit growth (4Y)4.3 %
- Promoter holding72.9 %
- EV / EBITDA10.5
- Beta0.48
- All-time high₹ 123
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| ANUHPHR | -7.45% | +3.03% | -0.16% | +2.55% | +3.60% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Anuh Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹828 crore.
- It trades at 18.7 times its last 12 months' earnings and 2.3 times book value.
- Revenue grew 13.5% a year over the last 4 years, profit 4.3% a year.
- Return on equity was 12.1% and return on capital employed 15.4% in the latest year.
- Debt was 0.00 times shareholders' equity.
- The share price is 17.0% below its 52-week high and up 3.6% over one year.
- Promoters and insiders hold about 72.9%; institutions about 0.0%.
Pros
AI- Company is almost debt-free (debt is 0.00 times equity).
- Healthy return on equity of 16.7% on average over the last 3 years.
- Promoters have raised their holding by 1.88 points over 7 quarters, to 71.80%.
- Pays a healthy dividend: about 36% of profit last year.
- Promoters hold a large stake of 71.80%.
Cons
AINo standout weaknesses in the reported figures.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Anuh Pharma Limited
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The company also develops products, such as anticoagulant, antagonist, anti convulsants, anty-ulcerative, anty-ulcerative, anticholinergics, anti-anemic, antidepressant, and mucolytic agents. It also exports its products. Anuh Pharma Limited was incorporated in 1960 and is headquartered in Mumbai, India.
- Employees
- 323
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Anuh Pharma | 82.57 | 18.7 | 828 | 1.79 | 11 | 37.63 | 194 | 3.93 | 15.4 | 12.1 | 2.35 | 7.4 | 0.00 | 72.89 | 772 | 13.5 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 568 | 35.00 | 4,031 | 30.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 38 Co. | 1,712.85 | 31.0 | 25,721 | 0.34 | 679 | 24.47 | 5,999 | 18.81 | 15.2 | 16.5 | 4.89 | 17.0 | 0.21 | 55.20 | 20,499 | 13.5 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Standalone figures in ₹ crore
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own past sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| 662 | 772 | 965 | |
| YOY Sales Growth % | 16.65% | ||
| 601 | 710 | 890 | |
| Material Cost % | 75% | 78% | 77% |
| Employee Cost % | 3% | 3% | 3% |
| Other Expenses % | 12% | 11% | 11% |
| Operating Profit | 61 | 62 | 75 |
| OPM % | 9% | 8% | 8% |
| Other Income | 9 | 4 | 10 |
| Interest | 1 | 0 | 0 |
| Depreciation | 9 | 11 | 14 |
| Profit before tax | 61 | 54 | 71 |
| 22% | 24% | 26% | |
| Current tax | 15 | 15 | |
| Deferred tax | -2 | -2 | |
| 47 | 41 | 52 | |
| YOY Profit Growth % | -13.32% | ||
| EPS in Rs | 4.73 | 4.10 | 5.24 |
| Dividend Payout % | 26% | 36% |
Compounded Sales Growth
- TTM:
- 5%
Compounded Profit Growth
- TTM:
- 12%
Stock Price CAGR
- 1 Year:
- 4%
Return on Equity
- 4 Years:
- 16%
- Last Year:
- 12%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 50 |
| Reserves | 216 | 266 | 301 | 302 |
| 1 | 3 | 11 | 0 | |
| Short term borrowings | 2 | 10 | ||
| 163 | 152 | 170 | 205 | |
| Trade payables | 153 | 141 | 157 | 188 |
| Current liabilities | 161 | 153 | 179 | 203 |
| Total Liabilities | 405 | 446 | 507 | 557 |
| 53 | 49 | 60 | 56 | |
| Gross block | 100 | 102 | 121 | 128 |
| Accumulated depreciation | 46 | 53 | 61 | 72 |
| Goodwill & intangibles | 0 | 0 | 0 | 1 |
| CWIP | 1 | 0 | 2 | 0 |
| 351 | 396 | 444 | 501 | |
| Inventories | 73 | 75 | 74 | 148 |
| Trade receivables | 171 | 190 | 216 | 239 |
| Cash & equivalents | 2 | 7 | 20 | 8 |
| Current assets | 308 | 339 | 376 | 451 |
| Total Assets | 405 | 446 | 507 | 557 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 54 | 13 | 37 | -3 | |
| Profit for the year | 36 | 60 | 47 | 41 |
| Working capital changes | 17 | -44 | -13 | -55 |
| Direct taxes paid | -13 | -19 | -11 | -13 |
| -43 | 1 | -20 | 18 | |
| Fixed assets purchased | -2 | -5 | -20 | -8 |
| Fixed assets sold | 0 | 0 | ||
| Investments purchased | -34 | -57 | ||
| Investments sold | 33 | 82 | ||
| -12 | -9 | -5 | -26 | |
| Interest paid | -0 | -0 | -0 | -1 |
| Dividends paid | -9 | -10 | -13 | -15 |
| Net Cash Flow | -2 | 5 | 12 | -11 |
| Free Cash Flow | 52 | 8 | 17 | -11 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 15.0% | 22.6% | 15.3% | 12.1% |
| ROCE | — | 19.6% | 26.8% | 18.8% | 15.4% |
| Operating margin | — | 8.4% | 10.5% | 8.6% | 7.4% |
| Net margin | — | 6.9% | 9.3% | 7.2% | 5.3% |
| Debt / equity | — | 0.00 | 0.01 | 0.03 | 0.00 |
| Current ratio | — | 1.91 | 2.22 | 2.11 | 2.22 |
| Debtor days | — | 118 | 107 | 119 | 113 |
| Inventory days | — | 66 | 57 | 54 | 90 |
| Days payable | — | 139 | 105 | 115 | 114 |
| Cash conversion cycle | — | 45 | 59 | 58 | 89 |
| Working capital days | — | 101 | 105 | 109 | 117 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 71.80%
- FIIs 0.01%
- Public 28.19%
| % | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 69.92% | 69.92% | 69.92% | 71.82% | 71.82% | 71.80% | 71.80% |
| 0.02% | 0.04% | 0.04% | 0.05% | 0.01% | |||
| Foreign portfolio investors (Cat. I) | 0.02% | 0.04% | 0.04% | 0.03% | 0.01% | ||
| Foreign portfolio investors (Cat. II) | 0.02% | ||||||
| 30.06% | 30.05% | 30.04% | 28.18% | 28.18% | 28.16% | 28.19% | |
| Retail (up to ₹2 lakh) | 19.53% | 19.48% | 19.48% | 17.28% | 17.15% | 17.03% | 16.89% |
| HNIs (above ₹2 lakh) | 6.50% | 6.44% | 6.41% | 6.58% | 6.59% | 6.53% | 6.60% |
| NRIs | 1.79% | 1.93% | 1.98% | 2.03% | 2.12% | 2.23% | 2.34% |
| Bodies corporate | 0.86% | 0.87% | 0.79% | 0.78% | 0.79% | 0.81% | 0.78% |
| IEPF | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.13% | 0.13% |
| No. of Shareholders | 24,279 | 24,235 | 24,257 | 28,250 | 27,889 | 27,425 | 27,484 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- AgreementsAnuh Pharma Limited has informed the Exchange about signing of Asset Transfer Agreement16-Oct-2026
- UpdatesAnuh Pharma Limited has informed the Exchange regarding 'proposal of Investment and availing of Loan'.13-Oct-2026
- Outcome of Board MeetingAnuh Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026 for Investment and availing of Loan.13-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201812-Oct-2026
- Trading WindowAnuh Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Action(s) taken or orders passedAnuh Pharma Limited has informed the Exchange about orders passed regarding receipt of Demand Order under Section 156 of the Income Tax Act, 1961.18-Sep-2026
- Change in ManagementAnuh Pharma Limited has informed the Exchange about change in Management14-Aug-2026
- AppointmentAnuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.14-Aug-2026
- General UpdatesAnuh Pharma Limited has informed the Exchange about General Updates under Regulation 30.14-Aug-2026
- Shareholders meetingAnuh Pharma Limited has submitted the Exchange a copy Voting Results and Scrutinizers report of Annual General Meeting held on August 12, 2026.14-Aug-2026
- Shareholders meetingAnuh Pharma Limited has informed the Exchange regarding Proceedings of 66th Annual General Meeting held on August 12, 202612-Aug-2026
- Copy of Newspaper PublicationAnuh Pharma Limited has informed the Exchange about Copy of Newspaper Publication of the Unaudited financial results for the Quarter ended 30th June, 2026, published in the Financ…09-Aug-2026
Annual reports
Credit ratings
Concalls & investor meets
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation19-Aug-2026
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation28-May-2026
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation13-Feb-2026
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation17-Nov-2025
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation22-Aug-2025
- Investor PresentationAnuh Pharma Limited has informed the Exchange about Investor Presentation29-May-2025
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 5 Aug 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
From the company (NSE)
- AgreementsAnuh Pharma Limited has informed the Exchange about signing of Asset Transfer AgreementNSE filing · 16-Oct-2026
- UpdatesAnuh Pharma Limited has informed the Exchange regarding 'proposal of Investment and availing of Loan'.NSE filing · 13-Oct-2026
- Outcome of Board MeetingAnuh Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026 for Investment and availing of Loan.NSE filing · 13-Oct-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 12-Oct-2026
- Trading WindowAnuh Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Action(s) taken or orders passedAnuh Pharma Limited has informed the Exchange about orders passed regarding receipt of Demand Order under Section 156 of the Income Tax Act, 1961.NSE filing · 18-Sep-2026
- Change in ManagementAnuh Pharma Limited has informed the Exchange about change in ManagementNSE filing · 14-Aug-2026
- AppointmentAnuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.NSE filing · 14-Aug-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Anuh Pharma Limited
What is the share price of Anuh Pharma Limited today?
What is the market cap of Anuh Pharma Limited?
What is the P/E ratio of Anuh Pharma Limited?
Is Anuh Pharma Limited a good investment?
How can I buy Anuh Pharma Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.